Is BPC-157 FDA Approved? What You Need to Know

The Short Answer

BPC-157 is not FDA approved. It has never entered formal clinical trials in humans. No pharmaceutical company has ever filed an Investigational New Drug (IND) application for BPC-157 with the FDA.

What BPC-157 does have is over 100 preclinical studies published across three decades, all originating from Predrag Sikiric's laboratory at the University of Zagreb. These studies demonstrate tissue-protective and regenerative effects across muscle, tendon, ligament, bone, gut, liver, and brain tissue in animal models. The consistency of these findings across multiple tissue types is why practitioners adopted BPC-157 for clinical use despite the absence of formal human trials.

What the Research Shows

BPC-157 is a 15-amino-acid peptide fragment derived from a larger protein called Body Protection Compound, which is naturally present in human gastric juice. Sikiric's lab first characterized it in 1991 and has published continuously since then. The research spans a remarkably wide range of tissue types and injury models:

Tendon and ligament healing. Multiple studies show accelerated tendon-to-bone healing, increased collagen organization, and faster functional recovery in transected Achilles tendon models. BPC-157 upregulates growth factors (VEGF, FGF, EGF) at the injury site.

Gastrointestinal protection. BPC-157 reduces gastric ulcers, heals esophageal lesions, protects against NSAID-induced gut damage, and improves outcomes in inflammatory bowel disease models. Its stability in the gastric environment (it comes from gastric juice) makes it uniquely suited for GI applications.

Muscle repair. Studies demonstrate faster muscle healing after crush injuries, with better fiber organization and less fibrosis compared to controls.

Organ protection. Liver, pancreas, and brain tissue all show protective effects in various toxicity and injury models. BPC-157 modulates the nitric oxide system, which is a central regulator of inflammation and blood flow throughout the body.

Sikiric P et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2018. View study

Why Has BPC-157 Never Gone Through Clinical Trials?

The short answer is economics, not safety. Running a drug through Phase 1-3 clinical trials and an FDA New Drug Application costs over $1 billion and takes 10 to 15 years. A pharmaceutical company only makes that investment when it can recoup the cost through patent-protected sales.

BPC-157 is a naturally occurring peptide fragment. You cannot patent a molecule that exists in human gastric juice. Without patent protection, any company that invested $1 billion in FDA approval would immediately face generic competition from compounding pharmacies. The return on investment is effectively zero.

This is not unique to BPC-157. Many naturally derived compounds with strong preclinical evidence never enter clinical trials for the same reason. The FDA approval process is designed for novel drug candidates that pharmaceutical companies can commercialize, not for naturally occurring peptides that anyone can compound.

How BPC-157 Is Regulated

BPC-157 is available as a compounded medication under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This means:

A licensed provider must prescribe it. You cannot legally obtain BPC-157 for therapeutic use without a prescription from a physician, nurse practitioner, or physician assistant.

A licensed pharmacy must prepare it. 503A pharmacies compound individual prescriptions under state board oversight. 503B outsourcing facilities are FDA-registered and inspected, with required batch testing for potency, sterility, and endotoxins.

It is not the same as "research peptides." Peptides sold online as "research chemicals" or "not for human use" are not compounded medications. They are not prescribed, not pharmacy-prepared, and not tested to pharmaceutical standards. The regulatory distinction matters for quality and safety.

FDA Context: What Approval Actually Means

FDA approval means one specific company proved one specific formulation works for one specific indication in controlled clinical trials. It does not mean all unapproved medications are unsafe. It does not mean approved medications are risk-free. Approximately 20% of all prescriptions in the United States are written for off-label uses of FDA-approved drugs.

For context, among growth hormone and recovery peptides, only Tesamorelin (Egrifta, approved 2010) has full FDA approval. CJC-1295, Ipamorelin, DSIP, TB-500, GHK-Cu, and most other peptides in clinical use are all compounded medications. BPC-157 is not an outlier in this regard. It is the norm for peptide therapy.

Sourcing and Quality: What to Look For

Because BPC-157 is compounded rather than commercially manufactured, quality varies by pharmacy. PeRx ships BPC-157 fully reconstituted and ready to use from licensed compounding pharmacies with potency testing, sterility testing, and endotoxin testing on every batch. Your vial arrives via FedEx Overnight in refrigerated packaging, ready for injection.

Frequently Asked Questions